About Cyclacel Pharmaceuticals

Alliances and Collaborations

Cyclacel Pharmaceuticals is interested in the following alliance frameworks:

Cyclacel Pharmaceuticals seeks partners for clinical stage programs after establishing registration indications and securing a regulatory route to market. Through informed early development and efficient and innovative clinical trial designs, Cyclacel Pharmaceuticals will derisk development programs prior to seeking a partner.

Cyclacel Pharmaceuticals seeks strategic partners for certain advanced preclinical programs where the mutually beneficial partnership can accelerate initiation of first-in-man studies, which are facilitated through partner resources and Cyclacel Pharmaceuticals' experience in translational biology and biomarker development.

In all cases, Cyclacel Pharmaceuticals looks to retain the right to continue to build on its existing infrastructure.

Our current collaboration includes the following organization:

The University of Texas M.D. Anderson Cancer Center

Cyclacel Pharmaceuticals, Inc. and The University of Texas MD Anderson Cancer Center entered into a three-year strategic alliance agreement that will enable clinical evaluation for safety and efficacy of three Cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and other advanced leukemias.

MD Anderson will conduct four clinical studies with a total projected enrollment of up to 170 patients, which will investigate CYC065, CYC140 and sapacitabine either as single agents or in combination with approved drugs. The collaboration leverages MD Anderson's expertise in clinical development of drugs for hematological malignancies and Cyclacel's novel drug portfolio that is based on the Company's knowledge of cell cycle biology and mechanisms of cancer cell resistance to medicines.

Please contact:

Research & Development